RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Betta Pharma of Hangzhou will pay up to $33.5 million in upfront and R&D milestones to in-license China rights for a third-generation EGFR inhibitor discovered by InventisBio (Shanghai). The two companies will co-develop the drug in China, but Betta will have exclusive commercialization rights. InventisBio is currently conducting a China Phase I trial of D-0316, a potential treatment for EGFR-mutant non-small cell lung cancer. Betta already offers China’s best-selling product for EFGR mutant lung cancer, icotinib (Conmana®).
Source: China Biotoday
